Carl Zeiss Meditec AG reaffirmed earning guidance for 2022. The Company's outlook for fiscal year 2021/22 remains unchanged: Revenue is expected to grow at least to the same extent as the market.
Market Closed -
Other stock markets
|
After market 01:28:01 am | |||
92.35 EUR | -2.69% | 91.82 | -0.57% |
08:35am | Goldman downgrades Carl Zeiss Meditec to 'Sell' - Target 90 euros | DP |
07:42am | CARL ZEISS MEDITEC AG : Downgraded from Neutral to Sell by Goldman Sachs | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.57% | 9.2B | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- AFX Stock
- News Carl Zeiss Meditec AG
- Carl Zeiss Meditec AG Reaffirms Earning Guidance for 2022